ZA8 Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Zymeworks Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.70 |
| 52 Week High | US$14.80 |
| 52 Week Low | US$7.40 |
| Beta | 1.13 |
| 1 Month Change | -13.97% |
| 3 Month Change | -8.59% |
| 1 Year Change | 23.05% |
| 3 Year Change | 91.33% |
| 5 Year Change | -52.05% |
| Change since IPO | 9.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZA8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 13.6% | 2.0% | 0.5% |
| 1Y | 23.1% | -8.6% | 15.4% |
Return vs Industry: ZA8 exceeded the German Biotechs industry which returned -8.6% over the past year.
Return vs Market: ZA8 exceeded the German Market which returned 15.4% over the past year.
Price Volatility
| ZA8 volatility | |
|---|---|
| ZA8 Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: ZA8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ZA8's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 283 | Ken Galbraith | www.zymeworks.com |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Zymeworks Inc. Fundamentals Summary
| ZA8 fundamental statistics | |
|---|---|
| Market cap | €783.19m |
| Earnings (TTM) | -€112.74m |
| Revenue (TTM) | €70.12m |
11.2x
P/S Ratio-6.9x
P/E RatioIs ZA8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZA8 income statement (TTM) | |
|---|---|
| Revenue | US$76.30m |
| Cost of Revenue | US$136.50m |
| Gross Profit | -US$60.19m |
| Other Expenses | US$62.50m |
| Earnings | -US$122.69m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.76 |
| Gross Margin | -78.89% |
| Net Profit Margin | -160.80% |
| Debt/Equity Ratio | 0% |
How did ZA8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 08:07 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zymeworks Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Arlinda Lee | Canaccord Genuity |
| Yigal Nochomovitz | Citigroup Inc |